Currently, there are no approved therapies for the treatment of NASH, but doctors recommend dietary changes and exercise to prevent or slow disease progression. Volixibat is a new experimental once-daily oral tablet that may improve NASH by targeting and blocking a protein (apical sodium-dependent bile acid transporter) found in the liver. This is thought to improve liver function by reducing the amount of cholesterol (fatty substance) in this organ. If licensed, volixibat has the potential to establish itself as a single-agent and the first treatment specifically for NASH.
Volixibat for non-alcoholic steatohepatitis (NASH)
Interventions: Volixibat (SHP626; LUM-002)
Indications: Non-alcoholic steatohepatitis (NASH)
Therapeutic Areas: Hepatology